ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Urological Cancer Drugs Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-39L3749
Home | Market Reports | Health| Men s Health
Global Urological Cancer Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Urological Cancer Drugs Market Research Report 2025

Code: QYRE-Auto-39L3749
Report
August 2025
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Pfizer Inc
Johnson & Johnson
Astrazeneca plc
Astellas
Bristol–Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline PLC
Indevus Pharmaceuticals Inc
Ipsen S A
Roche Healthcare
Sanofi
Tolmar

Urological Cancer Drugs Market

The global market for Urological Cancer Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Urological Cancer Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Urological Cancer Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Urological Cancer Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Urological Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urological Cancer Drugs.
The Urological Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Urological Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Urological Cancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Urological Cancer Drugs Market Report

Report Metric Details
Report Name Urological Cancer Drugs Market
Segment by Type
  • Tablets
  • Injection
Segment by Application
  • Prostate Cancer
  • Bladder Cancer
  • Kidney Cancer
  • Testicular Cancer
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, GlaxoSmithKline, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare, Sanofi S.A, Tolmar Inc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Urological Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Urological Cancer Drugs Market report?

Ans: The main players in the Urological Cancer Drugs Market are Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, GlaxoSmithKline, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare, Sanofi S.A, Tolmar Inc

What are the Application segmentation covered in the Urological Cancer Drugs Market report?

Ans: The Applications covered in the Urological Cancer Drugs Market report are Prostate Cancer, Bladder Cancer, Kidney Cancer, Testicular Cancer, Others

What are the Type segmentation covered in the Urological Cancer Drugs Market report?

Ans: The Types covered in the Urological Cancer Drugs Market report are Tablets, Injection

1 Urological Cancer Drugs Market Overview
1.1 Product Definition
1.2 Urological Cancer Drugs by Type
1.2.1 Global Urological Cancer Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Tablets
1.2.3 Injection
1.3 Urological Cancer Drugs by Application
1.3.1 Global Urological Cancer Drugs Market Value by Application (2024 VS 2031)
1.3.2 Prostate Cancer
1.3.3 Bladder Cancer
1.3.4 Kidney Cancer
1.3.5 Testicular Cancer
1.3.6 Others
1.4 Global Urological Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Urological Cancer Drugs Revenue 2020-2031
1.4.2 Global Urological Cancer Drugs Sales 2020-2031
1.4.3 Global Urological Cancer Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Urological Cancer Drugs Market Competition by Manufacturers
2.1 Global Urological Cancer Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Urological Cancer Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Urological Cancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Urological Cancer Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Urological Cancer Drugs, Product Type & Application
2.7 Global Key Manufacturers of Urological Cancer Drugs, Date of Enter into This Industry
2.8 Global Urological Cancer Drugs Market Competitive Situation and Trends
2.8.1 Global Urological Cancer Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Urological Cancer Drugs Players Market Share by Revenue
2.8.3 Global Urological Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Urological Cancer Drugs Market Scenario by Region
3.1 Global Urological Cancer Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Urological Cancer Drugs Sales by Region: 2020-2031
3.2.1 Global Urological Cancer Drugs Sales by Region: 2020-2025
3.2.2 Global Urological Cancer Drugs Sales by Region: 2026-2031
3.3 Global Urological Cancer Drugs Revenue by Region: 2020-2031
3.3.1 Global Urological Cancer Drugs Revenue by Region: 2020-2025
3.3.2 Global Urological Cancer Drugs Revenue by Region: 2026-2031
3.4 North America Urological Cancer Drugs Market Facts & Figures by Country
3.4.1 North America Urological Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Urological Cancer Drugs Sales by Country (2020-2031)
3.4.3 North America Urological Cancer Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Urological Cancer Drugs Market Facts & Figures by Country
3.5.1 Europe Urological Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Urological Cancer Drugs Sales by Country (2020-2031)
3.5.3 Europe Urological Cancer Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Urological Cancer Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Urological Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Urological Cancer Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Urological Cancer Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Urological Cancer Drugs Market Facts & Figures by Country
3.7.1 Latin America Urological Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Urological Cancer Drugs Sales by Country (2020-2031)
3.7.3 Latin America Urological Cancer Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Urological Cancer Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Urological Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Urological Cancer Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Urological Cancer Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Urological Cancer Drugs Sales by Type (2020-2031)
4.1.1 Global Urological Cancer Drugs Sales by Type (2020-2025)
4.1.2 Global Urological Cancer Drugs Sales by Type (2026-2031)
4.1.3 Global Urological Cancer Drugs Sales Market Share by Type (2020-2031)
4.2 Global Urological Cancer Drugs Revenue by Type (2020-2031)
4.2.1 Global Urological Cancer Drugs Revenue by Type (2020-2025)
4.2.2 Global Urological Cancer Drugs Revenue by Type (2026-2031)
4.2.3 Global Urological Cancer Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Urological Cancer Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Urological Cancer Drugs Sales by Application (2020-2031)
5.1.1 Global Urological Cancer Drugs Sales by Application (2020-2025)
5.1.2 Global Urological Cancer Drugs Sales by Application (2026-2031)
5.1.3 Global Urological Cancer Drugs Sales Market Share by Application (2020-2031)
5.2 Global Urological Cancer Drugs Revenue by Application (2020-2031)
5.2.1 Global Urological Cancer Drugs Revenue by Application (2020-2025)
5.2.2 Global Urological Cancer Drugs Revenue by Application (2026-2031)
5.2.3 Global Urological Cancer Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Urological Cancer Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis Urological Cancer Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Urological Cancer Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Company Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Company Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AstraZeneca Urological Cancer Drugs Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Astellas
6.5.1 Astellas Company Information
6.5.2 Astellas Description and Business Overview
6.5.3 Astellas Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Astellas Urological Cancer Drugs Product Portfolio
6.5.5 Astellas Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Abbott Laboratories
6.7.1 Abbott Laboratories Company Information
6.7.2 Abbott Laboratories Description and Business Overview
6.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
6.7.5 Abbott Laboratories Recent Developments/Updates
6.8 Celgene Corporation
6.8.1 Celgene Corporation Company Information
6.8.2 Celgene Corporation Description and Business Overview
6.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
6.8.5 Celgene Corporation Recent Developments/Updates
6.9 Dendreon Corporation
6.9.1 Dendreon Corporation Company Information
6.9.2 Dendreon Corporation Description and Business Overview
6.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
6.9.5 Dendreon Corporation Recent Developments/Updates
6.10 Ferring Pharmaceuticals
6.10.1 Ferring Pharmaceuticals Company Information
6.10.2 Ferring Pharmaceuticals Description and Business Overview
6.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
6.10.5 Ferring Pharmaceuticals Recent Developments/Updates
6.11 GlaxoSmithKline
6.11.1 GlaxoSmithKline Company Information
6.11.2 GlaxoSmithKline Description and Business Overview
6.11.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
6.11.5 GlaxoSmithKline Recent Developments/Updates
6.12 Indevus Pharmaceuticals Inc
6.12.1 Indevus Pharmaceuticals Inc Company Information
6.12.2 Indevus Pharmaceuticals Inc Description and Business Overview
6.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
6.12.5 Indevus Pharmaceuticals Inc Recent Developments/Updates
6.13 Ipsen
6.13.1 Ipsen Company Information
6.13.2 Ipsen Description and Business Overview
6.13.3 Ipsen Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Ipsen Urological Cancer Drugs Product Portfolio
6.13.5 Ipsen Recent Developments/Updates
6.14 Roche Healthcare
6.14.1 Roche Healthcare Company Information
6.14.2 Roche Healthcare Description and Business Overview
6.14.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
6.14.5 Roche Healthcare Recent Developments/Updates
6.15 Sanofi S.A
6.15.1 Sanofi S.A Company Information
6.15.2 Sanofi S.A Description and Business Overview
6.15.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
6.15.5 Sanofi S.A Recent Developments/Updates
6.16 Tolmar Inc
6.16.1 Tolmar Inc Company Information
6.16.2 Tolmar Inc Description and Business Overview
6.16.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
6.16.5 Tolmar Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Urological Cancer Drugs Industry Chain Analysis
7.2 Urological Cancer Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Urological Cancer Drugs Production Mode & Process Analysis
7.4 Urological Cancer Drugs Sales and Marketing
7.4.1 Urological Cancer Drugs Sales Channels
7.4.2 Urological Cancer Drugs Distributors
7.5 Urological Cancer Drugs Customer Analysis
8 Urological Cancer Drugs Market Dynamics
8.1 Urological Cancer Drugs Industry Trends
8.2 Urological Cancer Drugs Market Drivers
8.3 Urological Cancer Drugs Market Challenges
8.4 Urological Cancer Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
Pfizer Inc
Johnson & Johnson
Astrazeneca plc
Astellas
Bristol–Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline PLC
Indevus Pharmaceuticals Inc
Ipsen S A
Roche Healthcare
Sanofi
Tolmar
List of Tables
 Table 1. Global Urological Cancer Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Urological Cancer Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Urological Cancer Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Urological Cancer Drugs Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Urological Cancer Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Urological Cancer Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Urological Cancer Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Urological Cancer Drugs Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Urological Cancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Urological Cancer Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Urological Cancer Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Urological Cancer Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Urological Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Urological Cancer Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Urological Cancer Drugs Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Urological Cancer Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Urological Cancer Drugs Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Urological Cancer Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Urological Cancer Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Urological Cancer Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Urological Cancer Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Urological Cancer Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Urological Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Urological Cancer Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Urological Cancer Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Urological Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Urological Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Urological Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Urological Cancer Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Urological Cancer Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Urological Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Urological Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Urological Cancer Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Urological Cancer Drugs Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Urological Cancer Drugs Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Urological Cancer Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Urological Cancer Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Urological Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Urological Cancer Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Urological Cancer Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Urological Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Urological Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Urological Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Urological Cancer Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Urological Cancer Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Urological Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Urological Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Urological Cancer Drugs Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Urological Cancer Drugs Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Urological Cancer Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Urological Cancer Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Urological Cancer Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Urological Cancer Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Urological Cancer Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Urological Cancer Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Urological Cancer Drugs Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Urological Cancer Drugs Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Urological Cancer Drugs Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Urological Cancer Drugs Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Urological Cancer Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Urological Cancer Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Urological Cancer Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Urological Cancer Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Urological Cancer Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Urological Cancer Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Urological Cancer Drugs Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Urological Cancer Drugs Price (USD/Pcs) by Application (2026-2031)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Novartis Urological Cancer Drugs Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Pfizer Urological Cancer Drugs Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Johnson & Johnson Company Information
 Table 81. Johnson & Johnson Description and Business Overview
 Table 82. Johnson & Johnson Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Johnson & Johnson Urological Cancer Drugs Product
 Table 84. Johnson & Johnson Recent Developments/Updates
 Table 85. AstraZeneca Company Information
 Table 86. AstraZeneca Description and Business Overview
 Table 87. AstraZeneca Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. AstraZeneca Urological Cancer Drugs Product
 Table 89. AstraZeneca Recent Developments/Updates
 Table 90. Astellas Company Information
 Table 91. Astellas Description and Business Overview
 Table 92. Astellas Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Astellas Urological Cancer Drugs Product
 Table 94. Astellas Recent Developments/Updates
 Table 95. Bristol-Myers Squibb Company Information
 Table 96. Bristol-Myers Squibb Description and Business Overview
 Table 97. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. Bristol-Myers Squibb Urological Cancer Drugs Product
 Table 99. Bristol-Myers Squibb Recent Developments/Updates
 Table 100. Abbott Laboratories Company Information
 Table 101. Abbott Laboratories Description and Business Overview
 Table 102. Abbott Laboratories Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. Abbott Laboratories Urological Cancer Drugs Product
 Table 104. Abbott Laboratories Recent Developments/Updates
 Table 105. Celgene Corporation Company Information
 Table 106. Celgene Corporation Description and Business Overview
 Table 107. Celgene Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. Celgene Corporation Urological Cancer Drugs Product
 Table 109. Celgene Corporation Recent Developments/Updates
 Table 110. Dendreon Corporation Company Information
 Table 111. Dendreon Corporation Description and Business Overview
 Table 112. Dendreon Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 113. Dendreon Corporation Urological Cancer Drugs Product
 Table 114. Dendreon Corporation Recent Developments/Updates
 Table 115. Ferring Pharmaceuticals Company Information
 Table 116. Ferring Pharmaceuticals Description and Business Overview
 Table 117. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 118. Ferring Pharmaceuticals Urological Cancer Drugs Product
 Table 119. Ferring Pharmaceuticals Recent Developments/Updates
 Table 120. GlaxoSmithKline Company Information
 Table 121. GlaxoSmithKline Description and Business Overview
 Table 122. GlaxoSmithKline Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 123. GlaxoSmithKline Urological Cancer Drugs Product
 Table 124. GlaxoSmithKline Recent Developments/Updates
 Table 125. Indevus Pharmaceuticals Inc Company Information
 Table 126. Indevus Pharmaceuticals Inc Description and Business Overview
 Table 127. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 128. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product
 Table 129. Indevus Pharmaceuticals Inc Recent Developments/Updates
 Table 130. Ipsen Company Information
 Table 131. Ipsen Description and Business Overview
 Table 132. Ipsen Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 133. Ipsen Urological Cancer Drugs Product
 Table 134. Ipsen Recent Developments/Updates
 Table 135. Roche Healthcare Company Information
 Table 136. Roche Healthcare Description and Business Overview
 Table 137. Roche Healthcare Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 138. Roche Healthcare Urological Cancer Drugs Product
 Table 139. Roche Healthcare Recent Developments/Updates
 Table 140. Sanofi S.A Company Information
 Table 141. Sanofi S.A Description and Business Overview
 Table 142. Sanofi S.A Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 143. Sanofi S.A Urological Cancer Drugs Product
 Table 144. Sanofi S.A Recent Developments/Updates
 Table 145. Tolmar Inc Company Information
 Table 146. Tolmar Inc Description and Business Overview
 Table 147. Tolmar Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 148. Tolmar Inc Urological Cancer Drugs Product
 Table 149. Tolmar Inc Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Urological Cancer Drugs Distributors List
 Table 153. Urological Cancer Drugs Customers List
 Table 154. Urological Cancer Drugs Market Trends
 Table 155. Urological Cancer Drugs Market Drivers
 Table 156. Urological Cancer Drugs Market Challenges
 Table 157. Urological Cancer Drugs Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Urological Cancer Drugs
 Figure 2. Global Urological Cancer Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Urological Cancer Drugs Market Share by Type: 2024 & 2031
 Figure 4. Tablets Product Picture
 Figure 5. Injection Product Picture
 Figure 6. Global Urological Cancer Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Urological Cancer Drugs Market Share by Application: 2024 & 2031
 Figure 8. Prostate Cancer
 Figure 9. Bladder Cancer
 Figure 10. Kidney Cancer
 Figure 11. Testicular Cancer
 Figure 12. Others
 Figure 13. Global Urological Cancer Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Urological Cancer Drugs Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Urological Cancer Drugs Sales (2020-2031) & (K Pcs)
 Figure 16. Global Urological Cancer Drugs Average Price (USD/Pcs) & (2020-2031)
 Figure 17. Urological Cancer Drugs Report Years Considered
 Figure 18. Urological Cancer Drugs Sales Share by Manufacturers in 2024
 Figure 19. Global Urological Cancer Drugs Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Urological Cancer Drugs Players: Market Share by Revenue in Urological Cancer Drugs in 2024
 Figure 21. Urological Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Urological Cancer Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Urological Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 24. North America Urological Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Urological Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 28. Europe Urological Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Urological Cancer Drugs Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Urological Cancer Drugs Revenue Market Share by Region (2020-2031)
 Figure 36. China Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Urological Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Urological Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Urological Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Urological Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. U.A.E Urological Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Urological Cancer Drugs by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Urological Cancer Drugs by Type (2020-2031)
 Figure 58. Global Urological Cancer Drugs Price (USD/Pcs) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Urological Cancer Drugs by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Urological Cancer Drugs by Application (2020-2031)
 Figure 61. Global Urological Cancer Drugs Price (USD/Pcs) by Application (2020-2031)
 Figure 62. Urological Cancer Drugs Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Urological Cancer Therapeutics Drugs Market Research Report 2024
Global Urology Drugs Market Insights Forecast to 2030
Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Bladder Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oncology and Cancer Treatment Drug Market Research Report 2024
Urological Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urinary Tract Cancer Treatment Market Research Report 2024
Genitourinary Cancers Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti tumor Drug Market Research Report 2025
Cancer Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Head and Neck Squamous Cell Carcinoma Drugs Market Research Report 2024
Skin Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pet Cancer Targeted Drug Market Research Report 2024
Global Malignant Melanoma Drugs Market Research Report 2024
Global Renal Cell Cacinoma Drugs Market Research Report 2024
Testicular Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Castration resistant Prostate Cancer Drugs Market Research Report 2025
Global Advanced Prostate Cancer Drug Market Research Report 2025
Global Ovarian Cancer Drugs Market Insights Forecast to 2030
Global Urinary Products Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions